ASH 2019 – R/R B-cell NHL: mosunetuzumab shows promise in phase 1/1b trial

  • Ben Gallarda
  • Univadis
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.


  • The bispecific antibody mosunetuzumab demonstrated favorable safety and efficacy outcomes, including complete remission (CR) in patients with relapsed or refractory (R/R) B-cell non-Hodgkin lymphoma (NHL), even those with disease progression after chimeric antigen receptor T cell (CAR-T) therapy.
  • The drug could be potentially used before or after CAR-T therapy, as it is likely to boost responses in both cases.

Why this matters

  • Mosunetuzumab targets both CD3 (on T cell surfaces) and CD20 (on B cell surfaces), engaging T cells to elicit their cytotoxicity against B cells.
  • Unlike CAR T cells, which require a complex individualized production process lasting several weeks, mosunetuzumab is an off-the-shelf product.

Study design

  • Open-label, multicenter, phase 1/1b dose escalation and expansion trial.
  • Previously treated patients with R/R B-cell NHL (n=270) received mosunetuzumab (8 cycles for those achieving CR; maximum 17 cycles for those having partial response or stable disease).
  • Funding: Genentech Inc.

Key results

  • 67% patients had aggressive lymphomas, whereas 31% had indolent disease.
  • Among patients with aggressive lymphomas, 37% had objective responses and 19% achieved CR.
  • Among patients with indolent lymphomas, 63% had objective responses and 43% achieved CR.
  • Disease-free status was sustained in 71% of aggressive lymphoma and 83% of indolent lymphoma cases at 6 months since achieving CR.
  • In the subgroup of patients previously treated with CAR-T therapy (n=30), 38.9% had objective responses and 22% achieved CR.
  • The adverse event profile of mosunetuzumab was similar to that of CAR T cells.
  • Cytokine release syndrome, mostly mild, was seen in 29% of patients and moderately severe neurological toxicity was observed in 4% of patients.


  • Open-label design.

Expert commentary

  • The lead author, Stephen J Schuster, MD, of Abramson Cancer Center at the University of Pennsylvania in Philadelphia suggested that “initial use of mosunetuzumab would be in patients who have already tried CAR T cell therapy and had either not responded or relapsed – in lymphoma, this is about two-thirds of patients who are treated with this approach. This group of patients represents an unmet medical need, and this indication may be the quickest route to approval.”